Advertisement

Androgenetic alopecia in men and women

      Androgenetic alopecia is characterized by progressive, patterned hair loss from the scalp, and occurs in both men and women as well as in certain primates. The transition of some terminal hairs into vellus hairs is a near universal physiological secondary sexual characteristic,
      • Randall V.A.
      Androgens and human hair growth.
      therefore androgenetic alopecia only becomes a medical problem when the hair loss is subjectively viewed as excessive, premature, and distressing.
      • Sinclair R.
      • Banfield C.
      • Dawber R.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinics in Dermatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Randall V.A.
        Androgens and human hair growth.
        Clinical Endocrinology. 1994; 40: 439-457
        • Sinclair R.
        • Banfield C.
        • Dawber R.
        Handbook of diseases of the hair and scalp. Blackwell Science, Oxford1999
        • Hamilton J.B.
        Male hormone stimulation is a prerequisite and an incitant in common baldness.
        Am J Anat. 1942; 71: 451-480
        • Hamilton J.B.
        Effect of castration in adolescent and young adult males upon further changes in the proportion of bare and hairy scalp.
        J Clin Endocrinol Metabol. 1960; 20: 1309-1318
        • Simpson N.B.
        • Barth J.H.
        Hair patterns.
        in: Dawber R.P.R. Diseases of the hair and scalp. Blackwell Science, Oxford1997
        • Hamilton J.B.
        Male pattern hair loss in man.
        Ann NY Acad Sci. 1951; 53: 708-728
        • Messenger A.G.
        Androgen effects on hair growth.
        Dermatol Ther. 1998; 8: 7-17
        • Setty L.R.
        Hair patterns of the scalp of white and Negro males.
        Am J Phys Anthropol. 1970; 33: 49-55
        • Bruchner H.A.
        • Brown M.
        • Tretsa R.J.
        Baldness and emphysema.
        J Louisiana State Med Soc. 1964; 116: 329
        • Cotton S.G.
        • Nixon J.M.
        • Carpenter R.G.
        • et al.
        Factors discriminating men with coronary artery disease from healthy controls.
        Br H J. 1972; 34: 458
        • Trevisan M.
        • Farino E.
        • Krogh V.
        • et al.
        Baldness and coronary heart disease risk factors.
        J Clin Epidemiol. 1993; 46: 1213-1218
        • Cooke N.T.
        Male pattern alopecia and coronary artery disease.
        Br J Dermatol. 1979; 101: 455-458
        • Kligman A.M.
        The comparative histopathology of male pattern baldness and senescent baldness.
        Clin Dermatol. 1988; 6: 108-118
        • Whiting D.
        Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia.
        J Am Acad Dermatol. 1993; 28: 755-763
        • Curtois M.
        • Loussouarn G.
        • Horseau C.
        • et al.
        Hair cycle and alopecia.
        Skin Pharm. 1994; 7: 84-89
        • Kligman A.M.
        The human hair cycle.
        J Invest Dermatol. 1959; 33: 307-316
        • Oliver R.F.
        • Jahoda C.A.B.
        The dermal papilla and the maintenance of hair growth.
        in: Rogers G.A. Reis P.R. Ward K.A. The biology of wool and hair. Chapman and Hall, London1989: 51-67
        • Obana N.J.
        • Uno H.
        Dermal papilla cells in macaque alopecia trigger a testosterone-dependant inhibition of follicular cell proliferation.
        in: van Neste D. Randall V.A. Hair research in the next millennium. Elsevier, Amsterdam1996: 307-310
        • Randall V.A.
        The use of dermal papilla cells in studies of normal and abnormal hair follicle biology.
        Dermatol Clin. 1996; 14: 585-594
        • Van Scott E.J.
        • Ekel T.M.
        Geometric relationships between the matrix of the hair bulb and its dermal papilla in normal and alopecic scalp.
        J Invest Dermatol. 1958; 31: 281-287
        • Jahoda C.A.B.
        Cellular and developmental aspects of androgenetic aAlopecia.
        Exp Dermatol. 1998; 7: 235-248
        • Elliot K.
        • Stephenson T.J.
        • Messenger A.G.
        Differences in hair follicle dermal papilla volume are due to extracellular matrix volume and cell number.
        J Invest Dermatol. 1999; 113: 873-877
        • Rushton D.H.
        • Ramsay I.D.
        • Norris M.J.
        • et al.
        Natural progression of male pattern baldness in young men.
        Clin Exp Dermatol. 1991; 16: 188-192
        • Hutchinson P.E.
        • Thompson J.R.
        The cross-sectional size and shape of human terminal scalp hair.
        Br J Dermatol. 1997; 136: 159-165
        • Sinclair R.
        Male pattern androgenetic alopecia.
        Br Med J. 1998; 317: 865-869
        • Kaufman K.D.
        Androgen metabolism as it affects hair growth in androgenetic alopecia.
        Dermatol Clin. 1996; 14: 697-711
        • Griffin J.E.
        • Wilson J.D.
        The resistance syndromes.
        in: Baudet A.L. Sly W.S. Valle D. The metabolic basis of inherited disease. McGraw Hill, New York1989: 1919-1944
        • Imperato-McGinley J.
        • Guerrero L.
        • Gautier T.
        • et al.
        Steroid 5a reductase deficiency in man.
        Science. 1974; 186: 1213-1215
        • Kaufman K.D.
        Androgen metabolism as it affects hair growth in androgenetic alopecia.
        Dermatol Clin. 1996; 14: 697-711
        • Itami S.
        • Kurata S.
        • Sonoda T.
        • et al.
        Characterisation of 5a reductase in cultured dermal papilla cells from beard and occipital scalp hair.
        J Invest Dermatol. 1991; 96: 57-91
        • Thipgen A.
        • Silver R.
        • Guileyardo J.M.
        • et al.
        Tissue distribution and ontogeny of steroid 5a reductase isoenzyme expression.
        J Clin Invest. 1993; 92: 903-910
        • Bayne E.K.
        • Flanagan B.
        • Einstein M.
        • et al.
        Immunohistochemical localisation of types 1 and 2 5a reductase in human scalp.
        Br J Dermatol. 1999; 141: 481-491
        • Sreekumar Gp
        • Pardinas J.
        • Wong C.Q.
        • et al.
        Serum androgens and genetic linkage analysis in early onset androgenetic alopecia.
        J Invest Dermatol. 1999; 113: 277-279
        • Burton J.L.
        • Halim M.M.
        • Meyrick G.
        • et al.
        Male pattern alopecia and masculinity.
        Br J Dermatol. 1979; 100: 567-571
        • Sawaya M.E.
        Novel agents for the treatment of alopecia.
        Seminars Cutan Med Surg. 1998; 17: 276-283
        • O’Driscoll J.B.
        • Mamtora H.
        • Higginson
        • et al.
        A prospective study of the A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia.
        Clin-Endocrinol-Oxf. 1994; 41: 231-236
        • Thronton M.J.
        • Hamada K.
        • Messenger A.G.
        • et al.
        Androgen-dependant beard dermal papilla cells secrete autocrine growth factor(s) in response to testosterone unlike scalp cells.
        J Invest Dermatol. 1998; 111: 727-732
        • Norwood O.T.
        Male pattern baldness.
        South Medi J. 1975; 68: 1359-1365
        • Ludwig E.
        Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex.
        Brit J Dermatol. 1977; 97: 247-254
        • Kuhlwein A.
        Androgene Alopezie vom weiblichen Typ beim Mann.
        Z Hautkr. 1985; 60: 576-578
        • Norstrom R.E.
        Synchronous balding of scalp and hair bearing grafts of scalp transplanted to the skin of the arm in male pattern baldness.
        Acta Derm Venereol. 1979; 59: 266-268
        • Orentreich N.
        Autografts in alopecias and other selected dermatological conditions.
        Ann NY Acad Sci. 1959; 83: 462
        • Randall V.A.
        • Thornton M.J.
        • Messenger A.G.
        Cultured dermal papilla cells from androgen-dependent human hair follicles (eg beard) contain more androgen receptors than those from non-balding areas of the scalp.
        J Endocrinol. 1992; 133: 141-147
        • Boudou P.
        • Reygagne P.
        Increased scalp and serum 5a reductase reduced androgens in a man relevant to the acquired progressive kinky hair disorder and developing androgenetic alopecia.
        Arch Dermatol. 1997; 133: 1129-1133
        • Sawaya M.E.
        • Price V.E.
        Different levels of 5a reductase type I and II, aromatase, and androgen receptors in hair follicles of men and women with androgenetic alopecia.
        J Invest Dermatol. 1997; 109: 296-300
        • Thornton M.J.
        • Laing I.
        • Hamada K.
        • et al.
        Differences in testosterone metabolism by beard and scalp hair follicle dermal papilla cells.
        Clin Endocrinol. 1993; 39: 633-639
        • Itami S.
        • Kurata S.
        • Takayasu S.
        5a reductase activity in cultured dermal papilla cells from beard compared with reticular dermal fibroblasts.
        J Invest Dermatol. 1990; 94: 150-152
        • Kuster W.
        • Happle R.
        The inheritance of common baldness.
        J Am Acad Dermatol. 1984; 11: 921-926
        • Ellis J.A.
        • Stebbing M.
        • Harrap S.B.
        Analysis of candidate genes for androgenetic alopecia.
        Aust J Dermatol. 1997; 38: A317
        • Carey A.H.
        • Chan K.L.
        • Short F.
        • et al.
        Evidence for a single gene effect causing polycystic ovaries and male pattern baldness.
        Clin-Endocrinol-Oxf. 1993; 38: 653-658
        • Carey A.H.
        • Waterworth D.
        • Patel K.
        • et al.
        Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17.
        Hum-Mol-Genet. 1994; 3: 1873-1876
        • Franks S.
        • White D.
        • Gilling-Smith C.
        • et al.
        Hypersecretion of androgens by polycystic ovaries.
        Baillieres Clin Endocrinol Met. 1996; 10: 193-203
        • Ellis J.A.
        • Stebbing M.
        • Harrap S.B.
        Polymorphism of the androgen receptor gene is associated with male pattern baldness.
        J Invest Dermatol. 2001; 116: 452-455
      1. Cash TF. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol 1992;26:962–31.

        • Van Neste D.J.
        • Rushton D.H.
        Hair problems in women.
        Clin Dermatol. 1997; 15: 113-125
        • Cash T.F.
        Losing hair, losing points? The effects of male pattern baldness on social impression formation.
        J Appl Soc Psychol. 1990; 130: 209-218
        • Cash T.F.
        • Butters J.W.
        Poor body image.
        Med Asp Hum Sexual. 1988; 22: 67-70
        • Cash T.F.
        The psychosocial consequences of androgenetic alopecia.
        Br J Dermatol. 1999; 141: 398-405
        • Cash T.F.
        • Price V.H.
        • Savin R.C.
        Psychological effects of androgenetic alopecia on women.
        J Am Acad Dermatol. 1993; 29: 568-575
        • Kalick S.M.
        Psychological characteristics of alopecia patients.
        Arch Dermatol. 1994; 130: 907-908
        • Eckert J.
        Diffuse hair loss in women. The psychopathology of those who complain.
        Acta Psychiatr Scand. 1976; 53: 321-327
        • Chong A.H.
        • Wade M.
        • Sinclair R.D.
        The hair pull test and the hair pluck for analysis of hair abnormalities.
        Modern Medicine. 1999; 42: 105-108
        • Olsen E.A.
        The midline part.
        J Am Acad Dermatol. 1999; 40: 106-109
        • Sinclair R.
        Diffuse hair loss.
        Int J Dermatol. 1999; 38: 8-18
        • O’Driscoll J.B.
        • Mamtora H.
        • Higginson J.
        • et al.
        A prospective study of the prevalence of clear cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenetic alopecia.
        Clin Endocrinol Oxf. 1994; 41: 231-236
        • Venning V.A.
        • Dawber R.P.
        Patterned androgenetic alopecia in women.
        J Am Acad Dermatol. 1988; 18: 1073-1077
        • Whiting D.
        Chronic telogen effluvium.
        Dermatol Clin. 1996; 14: 697-711
        • Orentreich D.
        • Orentreich N.
        Androgenetic alopecia and its treatment, a historical view.
        in: Unger W.P. Hair transplantation. (3rd ed.). Marcel Dekker, New York1995: 1-16
        • Olsen E.A.
        • Buller T.A.
        • Weiner S.
        • et al.
        Natural history of androgenetic alopecia.
        Clin Exp Dermatol. 1990; 15: 34-36
      2. Hecht A. Hair grower and hair-loss prevention drugs. FDA Consumer 1985;(April 19):.

      3. Peluso AM, Misciali C, Vincenzi C, et al. Diffuse hypertrichosis during treatment with 5% minoxidil. Br J Dermatol 1997;136:118–12.

        • Devine B.L.
        • Fife R.
        • Trust P.M.
        Minoxidil for severe hypertension after failure of other hypotensive drugs.
        Br Med J. 1977; ii: 667
        • Ohtsuyama M.
        • Morhashi M.
        Minoxidil sulfate effect on internal calcium of cell in the epidermis and epidermal appendages.
        in: Van Neste D. Randall V. Hair research for the next millennium. Elsevier, Amsterdam1996: 481
        • Savin R.C.
        Use of topical minoxidil in the treatment of male pattern baldness.
        J Am Acad Dermatol. 1987; 16: 696-704
        • Olsen E.A.
        • De Long E.
        • Weiner M.S.
        Long term follow up of men with androgenetic alopecia treated with topical minoxidil.
        J Am Acad Dermatol. 1987; 16: 688
        • Olsen E.A.
        • Weiner M.S.
        Topical Minoxidil in male pattern baldness.
        J Am Acad Dermatol. 1987; 17: 97-101
      4. Bazzano GS, Terezakia N, Galen W. Topical tretinoin for hair growth promotion. J Am Acad Dermatol 1986;15: 880–3 and 890–3.

        • Dey R.
        • Donald T.G.
        Short and curly.
        MJA. 2000; 172: 47
        • Shapiro J.
        • Price V.H.
        Hair regrowth.
        Dermatol Ther. 1998; 16: 341-356
        • Rietschel R.L.
        • Duncan S.H.
        Safety and efficacy of topical minoxidil in the management of androgenetic alopecia.
        J Am Acad Dermatol. 1987; 16: 677-685
        • Drake L.
        • Hordinsky M.
        • Fiedler V.
        • et al.
        The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
        J Am Acad Dermatol. 1999; 41: 550-554
        • Roberts J.L.
        • Fiedler V.
        • Imperato-McGinley J.
        • et al.
        Clinical dose ranging studies with finasteride, a type 2 5 a reductase inhibitor, in men with male pattern hair loss.
        J Am Acad Dermatol. 1999; 41: 555-563
        • Kaufman K.D.
        • Olsen E.A.
        • Whiting D.
        • et al.
        Finasteride in the treatment of men with androgenetic alopecia.
        J Am Acad Dermatol. 1998; 39: 578-589
        • Leyden J.
        • Dunlap F.
        • Miller B.
        • et al.
        Finasteride in the treatment of men with frontal male pattern hair loss.
        J Am Acad Dermatol. 1999; 40: 930-937
        • Rushton D.H.
        • Norris M.J.
        • Ramsay I.D.
        Topical 0.05% finasteride significantly reduced serum DHT concentrations, but had no effect in preventing the expression of genetic hair loss in men.
        in: Van Neste D. Randall V.A. Hair research for the next millennium. Elsevier, Amsterdam1996: 359-362
        • DeVillez R.L.
        • Jacobs J.P.
        • Szpunar M.P.H.
        • et al.
        Androgenetic alopecia in the female. Treatment with 2% minoxidil solution.
        Arch Dermatol. 1994; 130: 303-307
        • Sinclair R.D.
        Common baldness in men and women.
        Modern Medicine. 1998; 41: 54-69
        • Olsen E.A.
        Androgenetic alopecia.
        in: Olsen E.A. Disorders of hair growth. Diagnosis and treatment. McGraw-Hill, New York1994: 274-278
        • Young R.
        • Sinclair R.D.
        Continuing medical education.
        Australas J Dermatol. 1998; 39: 24-28
      5. Young R, Sinclair RD. Continuing medical education: Hirsutes part 2. Australas J Dermatol 1998;39:151–17.

        • Burke B.M.
        • Cunliffe W.J.
        Oral spironolactone for female patients with acne, hirsutism or androgenetic alopecia.
        Br J Dermatol. 1985; 112: 124-125
        • Shaw J.C.
        Spironolactone in dermatological therapy.
        J Am Acad Dermatol. 1991; 24: 236-243
        • Neuman F.
        Pharmacological basis for clinical use of antiandrogens.
        J Steroid Biochem. 1983; 19: 391-402
        • Pereboom-Wynia J.D.
        • van der Willigen A.H.
        • van Joost
        • et al.
        The effects of cyproterone acetate on hair roots and hair shaft diameter in androgenetic alopecia in females.
        Acta Dermatol Venereol. 1989; 69: 395-398
        • Barth H.
        • Cherry C.A.
        • Wojnarowska F.
        Cyproterone acetate for severe hirsutism.
        J Clin Endocrin. 1991; 35: 5-10
        • Dawber R.P.R.
        • Sonnex T.
        • Ralfs I.
        Oral antiandrogen treatment of common baldness in women.
        Br J Dermatol. 1982; 107: 20
        • Van Wayjen R.G.
        • Van den Ende A.
        Experience in the long term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations.
        Exp Clin Endocrinol Diabetes. 1995; 103: 241-251
        • Barker D.J.P.
        The epidemiological evidence relating to spironolactone and malignant disease in man.
        J Drug Develop. 1987; 1: 22-25
        • Grigoriou O.
        • Papadias C.
        • Konidaris S.
        Comparison of flutamide and cyproterone acetate in the treatment of hirsutism.
        Gynecol Endocrinol. 1996; 10: 119-123
        • Cusan L.
        • Dupont A.
        • Gomez J.L.
        • et al.
        Comparison of flutamide and spironolactone in the treatment of hirsutism.
        Fertil Steril. 1995; 63: 680
      6. Roberts J, Hordinsky M, Olsen E, et al. The effects of finasteride on post-menopausal women with androgenetic alopecia. Hair Workshop. Brussels, May 2–5, 1998 (abst.).

        • Unger W.P.
        Surgical approach to hair loss.
        in: Olsen E.A. Disorders of hair growth. Diagnosis and treatment. McGraw-Hill, New York1994: 353-374
        • Auerback R.
        Dangers of synthetic fiber implantation for male pattern baldness.
        Cutis. 1980; 26: 416
        • Lepaw M.I.
        Complications of implantation of synthetic fibres into scalps for ’hair’ replacement.
        J Dermatol Surg Oncol. 1979; 5: 201-204
        • Chen W.
        • Zouboulis Ch.C.
        • Orfanos C.A.
        The 5a Reductase System and its inhibitors. Recent development and its perspective in treating androgen dependant skin disorders.
        Dermatology. 1996; 193: 177-184
        • Sinclair R.
        • Jones L.
        • Rivett D.E.
        Androgen metabolism and human hair growth.
        Chemistry in Australia. 1997; 64: 12-13
        • Li L.
        • Hoffman R.M.
        The feasibility of targeted selective gene therapy of the hair follicle.
        Nat-Med. 1995; 1: 705-706
        • Cotsarelis G.
        • Kaur P.
        • Dhouailly D.
        • et al.
        Epithelial stem cells in the skin.
        Exp Dermatol. 1999; 8: 80-88